Reed Jobs, son of tech legend Steve, steers Yosemite, an oncology‑focused venture firm launched in 2023. The firm blends philanthropy with traditional venture capital, building companies from academic discoveries. AI now underpins product development, clinical trial design, and drug discovery, turning the firm into a fast‑moving player.

Yosemite closed a second fund earlier this year, targeting $350 million. A third of the capital fuels companies created in‑house, while the remainder backs external ventures. The team grew to 17 members, and the firm runs a donor‑advised fund that receives 2.5 % of assets under management plus a $1 million annual fee. The model aims to de‑risk early‑stage ideas and accelerate market entry.

Pharma faces a historic patent cliff as blockbuster drugs lose protection, spurring a wave of acquisitions. Eli Lilly’s purchase of Kelonia for $7 billion illustrates отчёт, and Revolution Medicines’ KRAS therapy doubled survival for pancreatic cancer from 12 to 24 months. AI now trims Phase 3 trial costs—about $260 million—by generating synthetic control arms, cutting patient recruitment and speeding approvals.

Regulatory shifts add nuance. Federal budget proposals for NIH cuts have been rejected, keeping funding near 90 % approval. The FDA signals openness to AI‑driven trial designs, positioning Yosemite to exploit emerging pathways in oncology. Investors eye the firm’s dual strategy of building and partnering to capture opportunities before competitors.